The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; however, medical organizations and experts support the important role of SSRIs and other medications in supporting maternal mental health.
This study uncovers how trauma, isolation, loss of identity, and lack of support can overlap and amplify each other, deepening despair and driving suicide risk among women in the perinatal period.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; Dr. Freeman weighs in on the information provided in the report.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy but ignored or diminished the risks associated with untreated depression in the mother.Â
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy but ignored or diminished the risks associated with untreated depression in the mother.Â
This study provides valuable insight into the inequities in perinatal mental healthcare and suggests that the most significant barriers to mental healthcare may occur at the provider referral level.
In this prospective cohort study, the researchers observed an association between maternal depressive symptoms during pregnancy with slower rates of fetal growth.
Women who experienced depression during pregnancy were about four times as likely to experience PPD compared to women with no depression during pregnancy, with greater risk associated with depression during the first and third trimesters.
At 7 years of age, children exposed to maternal depression during pregnancy or SSRI antidepressants exhibited similar changes in white matter architecture.
There is evidence that screening for perinatal mood and anxiety disorders may improve outcomes; however, success depends on adequate resources for screening, diagnosis, treatment and follow-up.
